Analysis of RNAseq data taken from the TCGA study of 525 patients with primary head and neck cancer showed that patients with higher than median tumor ESR1 expression (ESR1> 5.56) had significantly better survival rates than patients with lower tumor ESR1 expression (Fig. 5A). This evidence concerns the gene ESR1 and head and neck cancer.